The_Company

THE COMPANY

MISSON STATEMENT

Profiles & Interventions is dedicated to becoming the premiere provider of supportive health services. We are committed to the continuous quality improvement of healthcare delivery by providing innovative solutions through our staff, clinical expertise and research technology.

OBJECTIVES

Profiles & Interventions, Inc. was founded in 1998 based on three principle objectives:

1) Provide unbiased, patient-centered, clinical pharmacist consultation services

2) Develop and implement evidenced-based quality improvement initiatives through research, education, and provider-specific clinical tools

3) Conduct unbiased and meaningful research aimed at improving health outcomes

COMPANY FOUNDER

Dr. Tommy E. Philpot is a 1993 graduate of Mercer University Southern School of Pharmacy where he received his Doctor of Pharmacy Degree (Pharm.D.). After completing his pharmacy internship at Emory University Hospital he was employed by Insta-care Pharmacy Services/ Pharmacy Corporation of America as a Clinical Consultant Pharmacist to skilled-nursing facilities. During his employment with PCA he conducted national drug usage evaluation and developed clinical software tools aimed at improving pharmaceutical-based patient care. In 1996 Tommy accepted a position with Eldercare Pharmacy where he co-developed Consultant Pharmacist Services provided to 43 skilled nursing facilities in Georgia. In 1998 Tommy founded APEX Health Outcomes, a quality improvement and consulting firm aimed at conducting Phase IV research and the provision of quality improvement and education services to managed-care and senior-care organizations. In early 2000, APEX Health Outcomes was renamed Profiles & Interventions, Inc (PI) to better describe the function of the company. Under his direction, the PI currently provides clinical pharmacy consultation services to skilled-nursing facilities and inpatient hospice units in Georgia. In addition, the firm provides quality improvement and research initiatives, along with, educational and clinical applications to approximately 300 senior-care pharmacies and consulting pharmacy organizations. Nationally, this alliance represents approximately 250,000 patient lives. Tommy has devoted the majority of his clinical practice to providing pharmaceutical consultation and education to senior adults, nursing home administration and other health practitioners. He has served on numerous clinical advisory panels within the pharmaceutical industry and professional speaking bureaus throughout his career. He is a past president of the Georgia chapter of the American Society of Consultant Pharmacists (GAASCP).

Professional Contributions and Activities (A complete listing available on request)

Bristol Myers-Squibb Distinguished Faculty Member in CNS Disorders 1995.

Bristol Myers-Squibb LTC Representative Training Session- The Role of Serzone in the Treatment of Geriatric Depression. Anecdotal Findings. Presented to regional LTC representatives. July 1996. (BMS)

Invited Speaker- Georgia Pharmaceutical Association Annual Meeting- Depression/ CNS Drugs in the Elderly Patient. 1 Hour CE program presented in Savannah, GA, June 1996. (Eli Lilly)

Advisory panel member, Eli Lilly Neuroscience Division 1998.

Invited Speaker- Evercare Group Atlanta Georgia- 1hr C.E. Recognizing the Depressed Geriatric Patient. November 1998 (Warner-Lambert)

Invited Speaker- Albany Alzheimer's Foundation, Albany, Georgia- Drug Interactions in the Elderly Population. February 1999.

Invited Speaker- Intravenous Nursing Society, Atlanta, Georgia- Antibiotics and Drug Interactions. 1 hour CE Program. March 1999.

Invited Speaker- Georgia Medical Directors Association, Chateau Elan, Georgia, NSAID Risk Identification in the LTC Patient. April 1999.

Invited Speaker- South Carolina Health Care Association, Myrtle Beach, SC. Recognizing the Depressed Geriatric Patient. (Warner-Lambert) April 1999.

10)

Invited Speaker- American Society of Consultant Pharmacists Midwestern Conference, Indianapolis, Indiana, How to be More Efficient as a Consultant Pharmacist- The Role of Technology. July 1999. (ACPE-approved program)

11)

Invited Speaker- Warner-Lambert Diabetes Advisory Panel Meeting, Miami, Fl. Progress Toward Meeting ADA Goals for Type II Diabetic Patients- A Presentation of Study Results. March 5, 2000.

12)

Invited Speaker- United Pharmacy Services Annual Meeting, Lake Lanier, GA. Coronary Disease and Hyperlipidemia in the Elderly- To Treat or Not to Treat. October, 2000. (Merck) (ACPE-approved program)

13)

Invited Speaker- The Medical Association of Georgia. Emory University Conference on Physician Profiling. Atlanta, GA. Building Profiling Studies. November 2000. (CME/ACPE-approved program)

14)

Invited Speaker- American Society of Consultant Pharmacists Annual Meeting. Boston, MA. The Appropriateness of Alendronate in the Geriatric Patient. Poster presentation and preliminary report of the study in progress. November, 2000.

15)

Invited Speaker- Gerimed Annual Seminar. Measuring Outcomes of Drug Therapy Interventions. Phoenix Arizona, July, 2000.

16)

Invited Speaker- Gerimed Annual Seminar. Improving Patient Outcomes Through Effective Use of Technology. Orlando, Florida, August, 2001.

17)

Invited Speaker- Gerimed Annual Seminar. Improving Patient Outcomes Through Effective Use of Technology. Newport, Rhode Island, August, 2002.

18)

Invited Speaker- Gerimed Annual Seminar. VTE: Treatment and Prevention of DVT. Ft. Lauderdale, Florida, July, 2003. (ACPE-approved program)

19)

Invited Speaker- Gerimed Annual Seminar. Using Technology and Clinical Algorithms for Improving Anticoagulation. Ft. Lauderdale, Florida, July, 2003. (ACPE-approved program)

20)

Invited Speaker- Gerimed Annual Seminar. VTE: Treatment and Prevention of DVT. Scottsdale, Arizona, August, 2003. (ACPE-approved program)

21)

Invited Speaker- Gerimed Annual Seminar. Using Technology and Clinical Algorithms for Improving Anticoagulation. Scottsdale, Arizona, August, 2003. (ACPE-approved program)

22)

Invited Speaker- Bightmoore Health Organization. A Review of Antipsychotic Drugs in Skilled-nursing Facility Patients. January, 2004.

23)

Invited Speaker- Crestview Health System. Quetiapine. Where does it fit in skilled-nursing facility patients? February, 2004.

24)

Invited Speaker- Georgia Society of Hospital Pharmacists Southwest Chapter Quarterly Meeting. A Review of Atypical Antipsychotic Therapy. (ACPE-approved program)

25)

Invited Speaker- American Society of Consultant Pharmacists 26th Midyear Conference and Exhibition. Scottsdale Arizona. 5-13-04. "Oral Anticoagulation: Preparing for Change" CE program for Consultant Pharmacists.

26)

Invited Speaker- GeriMed Annual Meeting and Exhibition. Norfolk, VA. 9-28-04. Using the MDS 2.0 for Identifying Depression and Hypertension Management for Stroke Prevention. CE program.

Additional Training

Completed a training module in geriatric depression at the Harvard Upper New England Geriatric Education Center- Harvard Medical School Division on Aging. June 1996.

Summary Clinical Development and/or Project Participation

1998

Interactive Depression Recognition and Treatment Tool for Nursing Facility Professionals. (included software database)- Eli Lilly

Comprehensive Diabetes Monitoring - included study protocol and data warehouse for benchmarking purposes- Proprietary Tool Used for Profiling Studies

Comprehensive Dyslipidemia Monitoring - included study protocol and data warehouse for benchmarking purposes- Proprietary Tool Used for Profiling Studies

1999-2000

Phase IV Pilot Program- Comprehensive Diabetes Care 1999: included profiling of 186 primary care physicians practicing in Georgia, South Carolina, Tennessee, and Virginia

Phase IV Study Development- Comprehensive Diabetes Care 2000: included 7 sites nationally, with 494 primary care physicians participating with a patient population of 6349. The study also included the development of an electronic data collection tool and statistical reporting system

Hospice Formulary Development and Printed Materials- PPS Pharmacy, Atlanta, GA.

Diabetes/ Dyslipidemia Profiling Studies Performed (n= 6,439)- included electronic data collection tool, data warehouse, statistical reporting and benchmarking: Parke-Davis Managed Care

Osteoporosis- Bisphosphonate Appropriateness Algorithm for Elderly Patients- Merck

The Appropriateness of Alendronate in the Long-term Care Patient (n=1000)- A retrospective analysis within a national pharmacy provider (APS). Included protocol development, case report form, data warehouse and statistical reporting. Data presented at the 2000 ASCP Convention, Boston, MA. Merck

LTC Profiles- Consultant Pharmacist Software and Database- Includes traditional reports, outcome tracking, disease management modules, custom recommendations, compliance reporting and data warehouse capabilities- Proprietary Product

2001

Osteoporosis Recognition Tool- Developed to screen patient admissions to nursing facilities for osteoporosis, using data from the MDS 2.0 that correlates with NOF criteria. Currently utilized by Physicians in the greater Detroit area- Merck

Osteoporosis Treatment Algorithm- developed in conjunction with a consulting software package utilized by Cornerstone Pharmacy, Indianapolis, IN. Merck

2002

LTC Physician PDA Project- Developed in conjunction with Emory University Medical School Center for Health and Aging. The scope of this project is aimed at reducing the risk of medical errors by providing on-screen information needed for improving patient care. The system also serves as a database for future data-mining capabilities.

Design and Preliminary Testing of Multifaceted Intervention to Reduce the Risk of Falls and Related Injuries Among Nursing Home Residents- Participation in project is in conjunction with Emory University Medical School Center for Health and Aging through a grant provided by The Agency for Healthcare Research and Quality. The role of Profiles & Interventions is to provide input concerning study methodology and to develop data mining and warehouse tools at the nursing facility level. (Grant obtained from AHRQ)

The GeriMed Disease Management and Research Initiative- GeriMed is a group purchasing organization for LTC Pharmacy Providers with a membership serving approximately 200,000 lives nationally. The scope of the project is aimed at providing disease management and educational tools to Consulting Pharmacists in order to initiate interventions regarding drug therapy in skilled-nursing facility patients. This project includes development of written and electronic materials to be used in conjunction with the GeriMed Profiles Consultant Pharmacist Software.

2003

Venous Thromboembolism- An Educational Toolkit for Senior-Care Pharmacists. Currently utilized by the GeriMed membership. Aventis

A Depression and Anxiety Resource Kit for Consultant Pharmacists- Currently in development for the GeriMed Membership. Wyeth

The Management of Hypertension in the Elderly Patient- An educational toolkit for Consultant Pharmacists. Wyeth

The Management of Anemia of Chronic Renal Failure in Skilled-Nursing Facility Patients- An Toolkit for Senior-Care Pharmacists. Amgen (Proposal Pending Acceptance)

2004

The Gerimed data harvesting project. Clinical data to be harvested and analyzed based on ICD-9 coding from the GeriMed Profiles Consultant Pharmacist Software.

The Management of Chronic Obstructive Pulmonary Disease in Skilled-Nursing Facility Patients- An Toolkit for Senior-Care Pharmacists. Boehringer

The Management of Insomnia in Skilled-Nursing Facility Patients- An Educational Toolkit for Skilled-Nursing Facility Pharmacists. Sanofi-Synthelabo

A 1:1 Conversion From Divalproex Delayed-Release to Divalproex Extended-Release: A Comparison of Tolerance in Skilled-Nursing Facility Patients with Dementia-Related Behavioral Disturbances. Research grant provided by Abbott Global Pharmaceutical Research and Development.

Last Updated- 10-04